NASDAQ:PRTA - Prothena Stock Price, Price Target & More

$10.99 -0.10 (-0.90 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$11.09
Today's Range$10.43 - $11.08
52-Week Range$10.43 - $70.00
Volume2.59 million shs
Average Volume797,846 shs
Market Capitalization$443.49 million
P/E Ratio-2.70
Dividend YieldN/A
Beta2.7

About Prothena (NASDAQ:PRTA)

Prothena logoProthena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTA
CUSIPN/A
Phone353-1236-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio11.41%
Quick Ratio11.41%

Price-To-Earnings

Trailing P/E Ratio-2.70
Forward P/E Ratio-2.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.52 million
Price / Sales15.40
Cash FlowN/A
Price / CashN/A
Book Value$10.59 per share
Price / Book1.04

Profitability

EPS (Most Recent Fiscal Year)($4.07)
Net Income$-153,230,000.00
Net Margins-556.84%
Return on Equity-33.37%
Return on Assets-27.92%

Miscellaneous

Employees125
Outstanding Shares38,560,000

How to Become a New Pot Stock Millionaire

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Corp (NASDAQ:PRTA) released its quarterly earnings results on Wednesday, February, 14th. The biotechnology company reported ($1.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.48) by $0.24. The biotechnology company had revenue of $0.23 million for the quarter, compared to analysts' expectations of $0.27 million. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The business's quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.41) earnings per share. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

12 brokers have issued 12 month price targets for Prothena's shares. Their forecasts range from $13.00 to $100.00. On average, they expect Prothena's stock price to reach $54.9091 in the next twelve months. View Analyst Ratings for Prothena.

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:
  • 1. According to Zacks Investment Research, "Prothena’s efforts to develop its pipeline are encouraging as late stage candidate, NEOD001 looks promising and a potential approval will boost prospects. Moreover, Prothena's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive as it not only boosts pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company recently entered into an agreement with Celgene as well.  However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates. Due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Shares have performed better than the industry in the last three months." (4/17/2018)
  • 2. Cantor Fitzgerald analysts commented, "Friday’s announcement that the CMO will resign her position may have created some disconcerting optics, but lacking any definitive details, we caution against over-interpreting the disclosure." (2/4/2018)

Who are some of Prothena's key competitors?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney Ph.D., Pres, CEO & Director (Age 49)
  • Mr. Tran B. Nguyen, Chief Financial Officer (Age 44)
  • Mr. Arthur W. Homan, Chief Legal Officer (Age 59)
  • Ms. Carol D. Karp, Chief Regulatory Officer (Age 65)
  • Dr. Martin Koller, Consultant (Age 67)

Has Prothena been receiving favorable news coverage?

News articles about PRTA stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $10.99.

How big of a company is Prothena?

Prothena has a market capitalization of $443.49 million and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Prothena employs 125 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 353-1236-2500 or via email at [email protected]


MarketBeat Community Rating for Prothena (PRTA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  343 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prothena (NASDAQ:PRTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Prothena in the last 12 months. Their average twelve-month price target is $54.9091, suggesting that the stock has a possible upside of 399.63%. The high price target for PRTA is $100.00 and the low price target for PRTA is $13.00. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.902.923.00
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.9091$75.80$76.4545$79.7273
Price Target Upside: 399.63% upside123.93% upside111.55% upside37.67% upside

Prothena (NASDAQ:PRTA) Consensus Price Target History

Price Target History for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018NomuraLower Price TargetBuy -> Buy$87.00 -> $19.00HighView Rating Details
4/24/2018WedbushLower Price TargetNeutral$46.00 -> $13.00HighView Rating Details
4/24/2018BTIG ResearchDowngradeBuy -> Neutral$77.00HighView Rating Details
4/24/2018Deutsche BankReiterated RatingBuy -> Buy$78.00 -> $16.00HighView Rating Details
4/24/2018Cantor FitzgeraldReiterated RatingOverweight -> Overweight$69.00 -> $14.00HighView Rating Details
4/23/2018OppenheimerDowngradeOutperform -> HoldHighView Rating Details
4/23/2018Royal Bank of CanadaDowngradeOutperform -> Sector Perform$87.00HighView Rating Details
4/23/2018BarclaysDowngradeOverweight -> Equal WeightHighView Rating Details
4/23/2018Jefferies GroupDowngradeBuy -> HoldHighView Rating Details
10/2/2017SunTrust BanksReiterated RatingBuy$75.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$83.00HighView Rating Details
5/16/2017Piper JaffrayReiterated RatingBuyMediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016UBSReiterated RatingBuy$73.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Prothena (NASDAQ:PRTA) Earnings History and Estimates Chart

Earnings by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) Earnings Estimates

2018 EPS Consensus Estimate: ($5.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.49)($0.83)($1.22)
Q2 20183($1.56)($0.83)($1.27)
Q3 20183($1.67)($0.73)($1.26)
Q4 20183($1.79)($0.50)($1.25)

Prothena (NASDAQ PRTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($1.44)N/AView Earnings Details
2/14/2018After Market($1.48)($1.24)$0.27 million$0.23 millionViewListenView Earnings Details
11/7/2017Q3($1.41)($1.37)$0.28 million$0.19 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.62)($0.55)$0.14 million$0.17 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.53)($0.64)$0.14 million$0.17 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.51)$0.17 millionViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.1270 million$0.5750 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Prothena (NASDAQ:PRTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Prothena (NASDAQ PRTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.70%
Insider Trading History for Prothena (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ PRTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017Dennis J SelkoeDirectorSell3,500$64.17$224,595.00View SEC Filing  
9/28/2017Christopher S HenneyDirectorSell900$70.00$63,000.00900View SEC Filing  
9/28/2017Gene G KinneyInsiderSell2,800$70.00$196,000.005,593View SEC Filing  
9/27/2017Tara NickersonInsiderSell4,724$69.05$326,192.206,724View SEC Filing  
9/25/2017Tara NickersonInsiderSell17,500$63.60$1,113,000.0019,500View SEC Filing  
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.005,000View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.006,345View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.003,000View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.006,345View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.003,200View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25413View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.007,845View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.3611,341View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.9017,578View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.003,000View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.007,000View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.003,125View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.509,375View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.003,025View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.002,000View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.007,845View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.002,000View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.002,200View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.502,845View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00243View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.002,000View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.252,845View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.003,333View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.008,161View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.002,000View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.002,793View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.002,200View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Prothena (NASDAQ PRTA) News Headlines

Source:
DateHeadline
Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout TargetProthena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target
seekingalpha.com - April 25 at 4:03 PM
Prothena: What Now?Prothena: What Now?
seekingalpha.com - April 25 at 4:03 PM
Lessons to Learn From April's Biotech BlowupsLessons to Learn From April's Biotech Blowups
finance.yahoo.com - April 25 at 4:03 PM
Prothena Corp. (PRTA) Has Plunged To A New Low After Drug DiscontinuedProthena Corp. (PRTA) Has Plunged To A New Low After Drug Discontinued
www.nasdaq.com - April 25 at 10:27 AM
Prothena Corp. (PRTA) Halts Development of NEOD001 for AL AmyloidosisProthena Corp. (PRTA) Halts Development of NEOD001 for AL Amyloidosis
www.streetinsider.com - April 25 at 10:27 AM
Prothena Ends Up With 2 Trial Failures, Becomes A Great Short OpportunityProthena Ends Up With 2 Trial Failures, Becomes A Great Short Opportunity
seekingalpha.com - April 25 at 10:27 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Prothena Corporation plc (PRTA)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Prothena Corporation plc (PRTA)
finance.yahoo.com - April 24 at 4:02 PM
Prothena, Akorn Plummet into Mondays 52-Week Low ClubProthena, Akorn Plummet into Monday's 52-Week Low Club
247wallst.com - April 24 at 9:55 AM
UPDATE: CORRECTION: BTIG Downgrades Prothena (PRTA) to NeutralUPDATE: CORRECTION: BTIG Downgrades Prothena (PRTA) to Neutral
www.streetinsider.com - April 24 at 9:55 AM
Prothena plunge dents Woodford portfolio after 2017 dropProthena plunge dents Woodford portfolio after 2017 drop
www.ft.com - April 24 at 9:55 AM
Prothena Shareholder Alert - PRTA Stock Drops Almost 70% - Kehoe Law Firm, P.C. InvestigatingProthena Shareholder Alert - PRTA Stock Drops Almost 70% - Kehoe Law Firm, P.C. Investigating
finance.yahoo.com - April 24 at 9:55 AM
Prothena (PRTA) PT Lowered to $19.00 at NomuraProthena (PRTA) PT Lowered to $19.00 at Nomura
www.americanbankingnews.com - April 24 at 9:29 AM
Wedbush Lowers Prothena (PRTA) Price Target to $13.00Wedbush Lowers Prothena (PRTA) Price Target to $13.00
www.americanbankingnews.com - April 24 at 9:29 AM
Prothena (PRTA) Given "Buy" Rating at Deutsche BankProthena (PRTA) Given "Buy" Rating at Deutsche Bank
www.americanbankingnews.com - April 24 at 8:58 AM
Prothena (PRTA) Downgraded to Neutral at BTIG ResearchProthena (PRTA) Downgraded to Neutral at BTIG Research
www.americanbankingnews.com - April 24 at 8:58 AM
Cantor Fitzgerald Reiterates Overweight Rating for Prothena (PRTA)Cantor Fitzgerald Reiterates Overweight Rating for Prothena (PRTA)
www.americanbankingnews.com - April 24 at 8:54 AM
Prothena (PRTA) Downgraded by Oppenheimer to "Hold"Prothena (PRTA) Downgraded by Oppenheimer to "Hold"
www.americanbankingnews.com - April 24 at 8:20 AM
ValuEngine Lowers Prothena (PRTA) to Strong SellValuEngine Lowers Prothena (PRTA) to Strong Sell
www.americanbankingnews.com - April 23 at 11:18 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prothena Corporation plc - PRTASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prothena Corporation plc - PRTA
www.prnewswire.com - April 23 at 7:13 PM
Prothena (PRTA) Downgraded by Jefferies Group to "Hold"Prothena (PRTA) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - April 23 at 4:34 PM
Prothena (PRTA) Rating Lowered to Sector Perform at Royal Bank of CanadaProthena (PRTA) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - April 23 at 4:34 PM
Prothena (PRTA) Stock Rating Lowered by BarclaysProthena (PRTA) Stock Rating Lowered by Barclays
www.americanbankingnews.com - April 23 at 4:34 PM
BUZZ-Woodford Patient Capital Trust takes Prothena hitBUZZ-Woodford Patient Capital Trust takes Prothena hit
www.lse.co.uk - April 23 at 4:01 PM
Prothena Shares Tumble Nearly 70% After It Scraps Rare Disease DrugProthena Shares Tumble Nearly 70% After It Scraps Rare Disease Drug
finance.yahoo.com - April 23 at 4:01 PM
Why Prothena Corporation plc Is Imploding TodayWhy Prothena Corporation plc Is Imploding Today
finance.yahoo.com - April 23 at 4:01 PM
Prothenas (PRTA) "In-Line" Rating Reaffirmed at Evercore ISIProthena's (PRTA) "In-Line" Rating Reaffirmed at Evercore ISI
www.americanbankingnews.com - April 23 at 10:54 AM
US STOCKS ON THE MOVE-Sears Holdings, Akorn, Michael Kors, McDermott, Flotek, HasbroUS STOCKS ON THE MOVE-Sears Holdings, Akorn, Michael Kors, McDermott, Flotek, Hasbro
www.nasdaq.com - April 23 at 9:58 AM
Endpoints NewsEndpoints News
www.benzinga.com - April 23 at 9:58 AM
BRIEF-Prothena Discontinues Development Of NEOD001 For Al AmyloidosisBRIEF-Prothena Discontinues Development Of NEOD001 For Al Amyloidosis
www.reuters.com - April 23 at 9:58 AM
Prothena shares plummet 60% on discontinued drugProthena shares plummet 60% on discontinued drug
finance.yahoo.com - April 23 at 9:58 AM
Prothena Discontinues Development of NEOD001 for AL AmyloidosisProthena Discontinues Development of NEOD001 for AL Amyloidosis
finance.yahoo.com - April 23 at 9:58 AM
[$$] Prothena goes splat[$$] Prothena goes splat
finance.yahoo.com - April 23 at 9:58 AM
Prothena Shares Tumble 60% After Scrapping Rare Disease DrugProthena Shares Tumble 60% After Scrapping Rare Disease Drug
finance.yahoo.com - April 23 at 9:58 AM
Prothena (PRTA) Lifted to "Buy" at Zacks Investment ResearchProthena (PRTA) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 1:54 PM
Prothena (PRTA) Stock Rating Upgraded by BidaskClubProthena (PRTA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 17 at 1:26 PM
Prothena (PRTA) Cut to "Buy" at BidaskClubProthena (PRTA) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
Prothena Corp (PRTA) Expected to Post Quarterly Sales of $6.53 MillionProthena Corp (PRTA) Expected to Post Quarterly Sales of $6.53 Million
www.americanbankingnews.com - April 13 at 2:18 AM
 Brokerages Anticipate Prothena Corp (PRTA) Will Post Earnings of -$1.24 Per Share Brokerages Anticipate Prothena Corp (PRTA) Will Post Earnings of -$1.24 Per Share
www.americanbankingnews.com - April 11 at 5:16 PM
Prothena (PRTA) Downgraded to Sell at ValuEngineProthena (PRTA) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 8:31 AM
Implied Volatility Surging for Prothena (PRTA) Stock Options April 09, 2018Implied Volatility Surging for Prothena (PRTA) Stock Options April 09, 2018
www.zacks.com - April 9 at 10:21 AM
Implied Volatility Surging for Prothena (PRTA) Stock OptionsImplied Volatility Surging for Prothena (PRTA) Stock Options
finance.yahoo.com - April 9 at 10:21 AM
Investors Buy Large Volume of Put Options on Prothena (PRTA)Investors Buy Large Volume of Put Options on Prothena (PRTA)
www.americanbankingnews.com - April 6 at 7:46 AM
Prothena Co. PLC (PRTA) Receives Consensus Recommendation of "Buy" from AnalystsProthena Co. PLC (PRTA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 5:40 PM
Prothena (PRTA) Given New $50.00 Price Target at BarclaysProthena (PRTA) Given New $50.00 Price Target at Barclays
www.americanbankingnews.com - April 5 at 2:29 PM
Prothena (PRTA) Lifted to Hold at ValuEngineProthena (PRTA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 1:10 PM
Investors Buy Large Volume of Prothena Call Options (PRTA)Investors Buy Large Volume of Prothena Call Options (PRTA)
www.americanbankingnews.com - April 4 at 8:10 AM
Prothena (PRTA) Downgraded by Zacks Investment ResearchProthena (PRTA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM
Acorda Files Parkinson's Drug Marketing Application in EUAcorda Files Parkinson's Drug Marketing Application in EU
finance.yahoo.com - March 27 at 4:11 PM
 Analysts Expect Prothena Co. PLC (PRTA) Will Announce Quarterly Sales of $280,000.00 Analysts Expect Prothena Co. PLC (PRTA) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - March 27 at 3:24 AM
Q1 2018 Earnings Forecast for Prothena Co. PLC (PRTA) Issued By WedbushQ1 2018 Earnings Forecast for Prothena Co. PLC (PRTA) Issued By Wedbush
www.americanbankingnews.com - March 26 at 1:02 AM

SEC Filings

Prothena (NASDAQ:PRTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Prothena (NASDAQ:PRTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Prothena (NASDAQ PRTA) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.